HomeCompareIOAC vs MRK

IOAC vs MRK: Dividend Comparison 2026

IOAC yields 20.83% · MRK yields 3.25%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 IOAC wins by $46.1K in total portfolio value
10 years
IOAC
IOAC
● Live price
20.83%
Share price
$9.60
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$76.8K
Annual income
$7,358.60
Full IOAC calculator →
MRK
Merck & Co. Inc.
● Live price
3.25%
Share price
$94.80
Annual div
$3.08
5Y div CAGR
8.2%
Payout ratio
42%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$950.29
Full MRK calculator →

Portfolio growth — IOAC vs MRK

📍 IOAC pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodIOACMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, IOAC + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
IOAC pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

IOAC
Annual income on $10K today (after 15% tax)
$1,770.83/yr
After 10yr DRIP, annual income (after tax)
$6,254.81/yr
MRK
Annual income on $10K today (after 15% tax)
$276.16/yr
After 10yr DRIP, annual income (after tax)
$807.75/yr
At 15% tax rate, IOAC beats the other by $5,447.06/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of IOAC + MRK for your $10,000?

IOAC: 50%MRK: 50%
100% MRK50/50100% IOAC
Portfolio after 10yr
$53.8K
Annual income
$4,154.45/yr
Blended yield
7.72%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

IOAC
No analyst data
Altman Z
-188.2
Piotroski
6/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+35.6% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

IOAC buys
0
MRK buys
0
No recent congressional trades found for IOAC or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricIOACMRK
Forward yield20.83%3.25%
Annual dividend / share$2.00$3.08
Payout ratio50%42%
1-year div growth0%5.5%
5-year div CAGR0%8.2%
Portfolio after 10y$76.8K$30.7K
Annual income after 10y$7,358.60$950.29
Total dividends collected$44.6K$6.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: IOAC vs MRK ($10,000, DRIP)

YearIOAC PortfolioIOAC Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$12,783$2,083.33$11,192$351.54+$1.6KIOAC
2$16,167$2,488.97$12,524$392.70+$3.6KIOAC
3$20,241$2,941.88$14,015$438.65+$6.2KIOAC
4$25,100$3,442.18$15,682$489.96+$9.4KIOAC
5$30,846$3,989.26$17,547$547.23+$13.3KIOAC
6$37,587$4,581.82$19,632$611.16+$18.0KIOAC
7$45,436$5,217.88$21,963$682.53+$23.5KIOAC
8$54,511$5,894.84$24,571$762.18+$29.9KIOAC
9$64,937$6,609.61$27,486$851.08+$37.5KIOAC
10$76,841$7,358.60$30,745$950.29+$46.1KIOAC

IOAC vs MRK: Complete Analysis 2026

IOACStock

Innovative International Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or other similar business transaction with one or more businesses in consumer technology, healthcare, information technology services, and enterprise software as a service. The company was incorporated in 2021 and is based in Dana Point, California.

Full IOAC Calculator →

MRKHealthcare

Merck is a Dividend Aristocrat with 14+ consecutive years of increases. Keytruda (pembrolizumab) is the world's best-selling cancer drug and drives exceptional cash generation. The company's oncology and vaccines pipeline provides long-term growth visibility beyond the Keytruda patent cliff in the 2030s.

Full MRK Calculator →
📬

Get this IOAC vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

IOAC vs SCHDIOAC vs JEPIIOAC vs OIOAC vs KOIOAC vs MAINIOAC vs JNJIOAC vs ABBVIOAC vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.